Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | LEAP-011: first-line pembrolizumab plus lenvatinib for UC

Yohann Loriot • 13 Feb 2020
GU Cancers 2020
Bladder Cancer Genitourinary Cancer Lenvatinib Pembrolizumab
LEAP-011

Yohann Loriot, MD, PhD, Gustave Roussy Institute & University of Paris-Saclay, Paris, France, discusses LEAP-011, a Phase III study of first-line pembrolizumab plus lenvatinib in patients with advanced urothelial carcinoma (UC) ineligible for platinum-based chemotherapy. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

More from Yohann Loriot

1:05
Future endeavours with ADCs in bladder cancer
Yohann Loriot • 5 Jun 2023
0:58
ADCs in the management of urothelial carcinoma
Yohann Loriot • 5 Jun 2023
0:49
Evolving landscape of urothelial cancer treatment: erdafitinib or enfortumab vedotin?
Yohann Loriot • 5 Jun 2023
1:22
Safety analysis of TROPHY-U-01 based on UGT1A1 status in mUC
Yohann Loriot • 5 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals